258
Participants
Start Date
November 30, 2012
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2014
Daclatasvir
Asunaprevir
Ribavirin
pegIFNα-2b
Telaprevir
Local Institution, Minato-ku
Local Institution, Bunkyo-ku
Local Institution, Bunkyo-ku
Local Institution, Shinagawa-ku
Local Institution, Musashino-shi
Local Institution, Kawasaki-shi
Local Institution, Yokohama
Local Institution, Chiba
Local Institution, Shimotsuke-shi
Local Institution, Saitama
Local Institution, Iruma-gun
Local Institution, Takasaki
Local Institution, Matsumoto
Local Institution, Chuo-shi
Local Institution, Izunokuni
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Toyoake Shi
Local Institution, Gifu
Local Institution, Ogaki-shi
Local Institution, Osaka
Local Institution, Osaka
Local Institution, Osaka
Local Institution, Suita
Local Institution, Suita-shi
Local Institution, Osaka-sayama-shi
Local Institution, Kyoto
Local Institution, Kashihara
Local Institution, Nishinomiya-shi
Local Institution, Okayama
Local Institution, Hiroshima
Local Institution, Fukuoka
Local Institution, Fukuoka
Local Institution, Fukuoka
Local Institution, Kurume
Local Institution, Nagasaki
Local Institution, Ōmura
Local Institution, Kumamoto
Local Institution, Kumamoto
Local Institution, Yufu
Local Institution, Kagoshima
Local Institution, Fukui-shi
Local Institution, Sendai
Local Institution, Yamagata
Local Institution, Obihiro-shi
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Takamatsu
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY